PhotoMedex Stock Rating Lowered by Canaccord Genuity (PHMD)
PhotoMedex (NASDAQ:PHMD) opened at 9.31 on Friday. PhotoMedex has a 52-week low of $8.50 and a 52-week high of $16.82. The stock has a 50-day moving average of $11.49 and a 200-day moving average of $13.46. The company has a market cap of $174.3 million and a price-to-earnings ratio of 20.04.
PhotoMedex (NASDAQ:PHMD) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.01 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.09 by $0.08. The company had revenue of $52.10 million for the quarter, compared to the consensus estimate of $62.10 million. During the same quarter in the prior year, the company posted $0.63 earnings per share. The company’s quarterly revenue was down 10.3% on a year-over-year basis. On average, analysts predict that PhotoMedex will post $0.20 earnings per share for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Ascendiant Capital Markets downgraded shares of PhotoMedex from a “buy” rating to a “hold” rating in a research note on Thursday, May 15th. They now have a $18.00 price target on the stock. Analysts at Maxim Group downgraded shares of PhotoMedex from a “buy” rating to a “hold” rating in a research note on Tuesday, May 13th. They now have a $20.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. PhotoMedex has a consensus rating of “Hold” and a consensus price target of $19.00.
PhotoMedex, Inc (NASDAQ:PHMD) is a Global Skin Health Solutions company that provides integrated disease management and aesthetic solutions to dermatologists, professional aestheticians and consumers.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.